Skip to main content

HFpEF and diabetes

Diagnosis and management in the wake of EMPEROR-Preserved

Keep up with the latest news on HFpEF

08-29-2021 | ESC 2021 | Conference coverage | News

Empagliflozin has broad beneficial effect on HFpEF outcomes

Empagliflozin treatment produces significant reductions in the risk for a broad range of inpatient and outpatient heart failure outcomes in people with a preserved ejection fraction, shows further analysis of EMPEROR-Preserved.

08-27-2021 | ESC 2021 | Conference coverage | News

EMPEROR-Preserved: A win for empagliflozin in HFpEF

Empagliflozin has become the first medication to demonstrate a clear protective effect in people with heart failure and preserved ejection fraction, report the EMPEROR-Preserved investigators.

05-17-2021 | ACC 2021 | Conference coverage | News

Heart failure benefits of sotagliflozin consistent in preserved ejection fraction

The protective effect of sotagliflozin in people with type 2 diabetes and heart failure extends to those who have preserved ejection fraction, shows a prespecified pooled analysis of SOLOIST-WHF and SCORED.

Experts discuss the clinical implications of EMPEROR-Preserved

08-29-2021 | ESC 2021 | Conference coverage | Video

EMPEROR-Preserved: The implications for primary care

Kevin Fernando discusses the EMPEROR-Preserved findings and their likely impact on the treatment of people with heart failure with preserved ejection fraction, with or without diabetes, in primary care.

08-29-2021 | ESC 2021 | Conference coverage | Video

EMPEROR-Preserved: Diabetes medication becomes first effective HFpEF therapy

EMPEROR-Preserved investigator Stefan Anker discusses the role of SGLT2 inhibitors in patients with heart failure.

Stay informed with Medicine Matters

Get the latest developments in diabetes delivered straight to your inbox

Image Credits